BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company that develops and markets products to treat life-threatening genetic conditions. The company focuses on translating genetic discoveries into new medicines and collaborating with patient communities to improve care.

BioMarin

BioMarin Italia

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact.


Recruitment Fraud Alert Notice
 
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral.
 
In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.
 
If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit.

We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.


Our employees came together to assemble 180 back-to-school backpacks for students in our community last week. We put together backpacks for students in kindergarten through 12th grade, filling the backpacks with essentials for the school year. This event was sponsored by Life Science Cares Bay Area, an organization that works within the life science industry to fight poverty and inequalities. We donated the backpacks  to Ritter Center, a local organization that provides services to Marin County residents experiencing economic insecurities and homelessness. Thank you to our employees and to Life Science Cares Bay Area for making an impact in our community!

We’ve welcomed the first high school interns to BioMarin, in collaboration with Biotech Partners – a nonprofit organization dedicated to building biotech career skills among Bay Area youth. Enehemias and Paige are spending eight weeks this summer in our San Rafael labs, learning all about bench research from BioMarin scientists. Enehemias is spearheading the consolidation of our cell line storage databases, while Paige is conducting an energy efficiency analysis of our refrigeration systems. We’re proud to support these scientists-in-training and help cultivate the next generation of biotech leaders.

Today on National Intern Day, we are celebrating this year’s group of BioMarin interns, who we welcomed at the beginning of summer. Our skilled and innovative interns are working across a range of teams, including Finance, Legal, Technical Development, Quality, and Research. Their hard work is helping BioMarin address the unmet need for people living with genetic conditions. Thank you #BioMarininterns

Today we announced second-quarter 2024 results. Learn more: https://bit.ly/4dzceZN

For children living with achondroplasia, height is only one of the many factors to consider. To support children and families impacted by this condition, it’s crucial to apply a holistic approach that addresses all the unique challenges potentially faced.

There’s more to the conversation in achondroplasia than height alone. We’re committed to understanding the holistic experiences and challenges people living this condition face.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	548.49M -	751.04M 36.93%	889.89M 18.49%	1.12B 25.50%	1.31B 17.62%	1.49B 13.52%	1.70B 14.27%	1.86B 9.18%	1.85B 0.76%	2.10B 13.53%	2.42B 15.42%
cost of revenue	95.74M -	129.76M 35.54%	152.01M 17.14%	209.62M 37.90%	241.79M 15.34%	315.26M 30.39%	359.47M 14.02%	524.27M 45.85%	470.51M 10.25%	483.67M 2.80%	577.07M 19.31%
gross profit	452.74M -	621.28M 37.22%	737.89M 18.77%	907.23M 22.95%	1.07B 18.15%	1.18B 9.71%	1.34B 14.34%	1.34B 0.62%	1.38B 2.96%	1.61B 17.20%	1.84B 14.25%
selling and marketing expenses								403.40M -	405.10M 0.42%	450.30M 11.16%	488.40M 8.46%
general and administrative expenses	235.36M -	302.16M 28.38%	402.27M 33.13%	476.59M 18.48%	554.34M 16.31%	604.35M 9.02%		334.30M -	354.30M 5.98%	403.71M 13.95%	448.90M 11.19%
selling general and administrative expenses	235.36M -	302.16M 28.38%	402.27M 33.13%	476.59M 18.48%	554.34M 16.31%	604.35M 9.02%	680.92M 12.67%	737.67M 8.33%	759.38M 2.94%	854.01M 12.46%	937.79M 9.81%
research and development expenses	354.78M -	461.54M 30.09%	634.81M 37.54%	661.90M 4.27%	610.75M 7.73%	696.33M 14.01%	715.01M 2.68%	628.12M 12.15%	628.79M 0.11%	649.61M 3.31%	746.77M 14.96%
other expenses	982K -	279K 71.59%	-9.30M 3,432.97%	4.93M 153.01%	7.97M 61.70%	2.21M 72.33%	74.11M 3,260.91%	66.66M 10.05%	69.93M 4.91%	67.19M 3.92%	-10.54M 115.68%
cost and expenses	704.49M -	911.43M 29.37%	1.17B 28.52%	1.32B 12.79%	1.45B 10.00%	1.66B 14.55%	1.83B 9.90%	1.96B 6.95%	1.93B 1.44%	2.05B 6.53%	2.26B 10.08%
operating expenses	608.75M -	781.67M 28.41%	1.02B 30.41%	1.11B 9.04%	1.21B 9.00%	1.35B 11.38%	1.47B 8.93%	1.43B 2.56%	1.46B 1.79%	1.57B 7.73%	1.68B 7.24%
interest expense	10.45M -	36.64M 250.74%	38.24M 4.37%	39.50M 3.28%	42.71M 8.12%	43.66M 2.24%	23.46M 46.27%	29.31M 24.93%	15.34M 47.67%	15.97M 4.13%	17.34M 8.55%
ebitda	-118.79M -	-137.76M 15.97%	-287.28M 108.54%	-192.43M 33.02%	-71.70M 62.74%	-100.25M 39.82%	-22.24M 77.81%	-5.85M 73.70%	48.03M 920.96%	159.51M 232.14%	261.98M 64.24%
operating income	-156.01M -	-92.89M 40.46%	-110.70M 19.17%	-803.43M 625.76%	-14.70M 98.17%	-123.52M 740.30%	-125.46M 1.56%	-96.26M 23.27%	-60.01M 37.66%	57.55M 195.89%	157.60M 173.86%
depreciation and amortization	47.26M -	17.97M 61.98%	-17.69M 198.45%	-26.95M 52.36%	46.47M 272.41%	48.79M 4.99%	103.21M 111.54%	90.41M 12.41%	108.04M 19.50%	101.97M 5.62%	104.39M 2.37%
total other income expenses net	-167K -	66.90M 40,161.08%	160.68M 140.18%	-594.73M 470.13%	131.68M 122.14%	51.65M 60.77%	30.65M 40.67%	53.94M 76.00%	-15.34M 128.43%	92.03M 700.05%	30.97M 66.35%
income before tax	-176.50M -	-124.87M 29.25%	-154.72M 23.91%	-831.05M 437.12%	-35.88M 95.68%	-142.71M 297.78%	-94.81M 33.56%	-42.32M 55.36%	-75.35M 78.04%	149.58M 298.51%	188.56M 26.07%
income tax expense	-150K -	9.10M 6,167.33%	17.07M 87.62%	-200.84M 1,276.22%	81.17M 140.41%	-65.49M 180.69%	-70.96M 8.35%	-901.42M 1,170.27%	-11.27M 98.75%	8.02M 171.12%	20.92M 160.99%
net income	-176.35M -	-133.97M 24.03%	-171.80M 28.24%	-630.21M 266.83%	-117.04M 81.43%	-77.21M 34.03%	-23.85M 69.11%	859.10M 3,702.40%	-64.08M 107.46%	141.56M 320.91%	167.65M 18.43%
weighted average shs out	137.75M -	146.35M 6.24%	160.03M 9.34%	165.99M 3.72%	174.43M 5.09%	177.06M 1.51%	179.04M 1.12%	180.80M 0.99%	182.85M 1.13%	185.27M 1.32%	187.83M 1.39%
weighted average shs out dil	137.75M -	146.35M 6.24%	160.03M 9.34%	166.22M 3.87%	174.43M 4.94%	177.27M 1.63%	179.04M 1.00%	191.68M 7.06%	182.85M 4.60%	188.96M 3.34%	191.59M 1.39%
eps	-1.28 -	-0.92 28.13%	-1.07 16.30%	-3.80 255.14%	-0.67 82.37%	-0.44 34.33%	-0.13 70.45%	4.72 3,730.77%	-0.35 107.42%	0.76 317.14%	0.87 14.47%
epsdiluted	-1.28 -	-0.92 28.13%	-1.07 16.30%	-3.79 254.21%	-0.67 82.32%	-0.44 34.33%	-0.13 70.45%	4.50 3,561.54%	-0.35 107.78%	0.75 314.29%	0.87 16%

COM:BIOMARIN

BioMarin

Last Close

62.56

21/11 21:00

Market Cap

15.63B

Beta: -

Volume Today

1.23M

Avg: -

Preview